LEVERKUSEN, Germany (Reuters) — Bayer forecast a year without earnings growth for its agricultural products business late last month as it seeks to complete its US$66 billion deal to take over American seed giant Monsanto.
The German company has said the deal, which would put the size of its agricultural business on a par with its health care unit in terms of revenues, would enable it to develop new combinations of seeds and pesticides to compete against big rivals such as Dow and DuPont, which plan to merge their agricultural businesses.
Read Also
Farming Smarter receives financial boost from Alberta government for potato research
Farming Smarter near Lethbridge got a boost to its research equipment, thanks to the Alberta government’s increase in funding for research associations.
However, in 2017 Bayer’s Crop Science division is expected to produce underlying earnings before interest, taxes, depreciation and amortization unchanged from last year, the group said Feb. 22 in reporting fourth-quarter group earnings that slightly beat market expectations.
“We’ve had outstanding harvests over the last three years, resulting in a certain oversupply in crops and a cyclical dent in our business,” said Liam Condon, head of Bayer’s Crop Science unit, adding that the trend could soon change.
“Given the likelihood of extreme weather phenomena, it doesn’t take much for the cycle to turn.”
A recovery in demand was likely to be seen first in Asia, Eastern Europe and Latin America toward the end of 2017, while markets in North America and Europe would not see a return to more robust growth before 2018.
Bayer said in its annual report it expected seed and crop protection market growth of one percent this year compared with a one percent decline in 2016.
Prices of agricultural commodities such as corn, soy and wheat have recovered somewhat from multi-year lows hit in September last year.
The group also said it was on track to gain all regulatory approvals for the takeover by year-end, with Condon saying that this forecast anticipated a likely in-depth investigation by the European Union’s competition regulators.
Bayer said earlier this winter that its chief executive officer, Werner Baumann, and his counterpart at Monsanto had had a “productive” meeting with Donald Trump before Trump took office as president, to discuss the proposed merger.
For the group overall, Bayer predicted a medium single-digit percentage increase in adjusted EBITDA for 2017, helped by fast-growing revenues from stroke prevention pill Xarelto.
In the fourth quarter, adjusted group EBITDA rose 13.7 percent to $2.30 billion.
Growth in prescription drugs sales were partly offset by weaker than expected earnings at its consumer care products division, with sales of allergy treatment Claritin falling nine percent, coming under pressure from rival products.
